| Issue Date |
Title |
Author(s) |
| Jun-2020 |
Comparison of the Efficacy and Safety of Adalimumab (Humira) and the Adalimumab Biosimilar Candidate (HS016) in Chinese Patients with Active Ankylosing Spondylitis: A Multicenter, Randomized, Double-Blind, Parallel, Phase III Clinical Trial |
Su, Jinmei;Li, Mengtao;He, Lan;Zhao, Dongbao;Wan, Weiguo;Liu, Yi;Xu, Jianhua;Xu, Jian;Liu, Huaxiang;Jiang, Lindi;Wu, Huaxiang;Zuo, Xiaoxia;Huang, Cibo;Liu, Xiumei;Li, Fen;Zhang, Zhiyi;Liu, Xiangyuan;Dong, Lingli;Li, Tianwang;Chen, Haiying;Li, Jingyang;He, Dongyi;Lu, Xin;Huang, Anbin;Tao, Yi;Wang, Yanyan;Zhang, Zhuoli;Wei, Wei;Li, Xiaofeng;Zeng, Xiaofeng |
| Sep-2020 |
Development and formulation of the classification criteria for osteoarthritis |
Huang, Cibo;Zhang, Zhiyi;Chen, Yaolong;Zhang, Yue;Xing, Dan;Zhao, Like;Lin, Jianhao;Mei, Yifang;Lin, Hsiao-Yi;Zheng, Yi;Tsai, Wei-Chung;Liu, Shengyun;Jiang, Quan;Liu, Yi;Chen, Jinwei;Ye, Zhizhong;Chen, Min;Chen, Yingjuan;Chu, Cong-Qiu;Gao, Ming;He, Lan;Lin, Jin;Wu, Lijun;Xu, Jianhua;Yang, Pinting;Zhang, Xuewu;Jiang, Qing;Lei, Guanghua;Li, Mengtao;Yang, Wanling;Gu, Xin;Zhou, Yixin;He, Dongyi;Liu, Wei;Zhang, Weiya;Ding, Changhai;Zeng, Xiaofeng |
| Oct-2020 |
Guidelines for the diagnosis and treatment of osteoarthritis in China (2019 edition) |
Zhang, Zhiyi;Huang, Cibo;Jiang, Quan;Zheng, Yi;Liu, Yi;Liu, Shengyun;Chen, Yingjuan;Mei, Yifang;Ding, Changhai;Chen, Min;Gu, Xin;Xing, Dan;Gao, Min;He, Lan;Ye, Zhizhong;Wu, Lijun;Xu, Jianhua;Yang, Pinting;Zhang, Xuewu;Zhang, Yue;Chen, Jinwei;Lin, Jin;Zhao, Like;Li, Mengtao;Yang, Wanling;Zhou, Yixin;Jiang, Qing;Chu, Cong-Qiu;Chen, Yaolong;Zhang, Weiya;Tsai, Wei-Chung;Lei, Guanghua;He, Dongyi;Liu, Wei;Fang, Yongfei;Wu, Darong;Lin, Jianhao;Wei, Cheng-Chung;Lin, Hsiao-Yi;Zeng, Xiaofeng |
| 2017 |
High-Throughput Study of the Effects of Celastrol on Activated Fibroblast-Like Synoviocytes from Patients with Rheumatoid Arthritis |
Fang, Zhengyu;He, Dongyi;Yu, Bo;Liu, Feng;Zuo, Jianping;Li, Yuxia;Lin, Qi;Zhou, Xiaodong;Wang, Qingwen |
| 2014 |
Novel Risk Loci for Rheumatoid Arthritis in Han Chinese and Congruence With Risk Variants in Europeans |
Jiang, Lei;Yin, Jian;Ye, Lingying;Yang, Jian;Hemani, Gibran;Liu, Ai-Jun;Zou, Hejian;He, Dongyi;Sun, Lingyun;Zeng, Xiaofeng;Li, Zhanguo;Zheng, Yi;Lin, Yiping;Liu, Yi;Fang, Yongfei;Xu, Jianhua;Li, Yinong;Dai, Shengming;Guan, Jianlong;Jiang, Lindi;Wei, Qianghua;Wang, Yi;Li, Yang;Huang, Cibo;Zuo, Xiaoxia;Liu, Yu;Wu, Xin;Zhang, Libin;Zhou, Ling;Zhang, Qing;Li, Ting;Chen, Ling;Xu, Zhen;Yang, Xiaoping;Qian, Feng;Xie, Weilin;Liu, Wei;Guo, Qian;Huang, Shaolan;Zhao, Jing;Li, Mengmeng;Jin, Yanhua;Gao, Jie;Lv, Ying;Wan |
| Apr-2021 |
Patient-reported outcomes from a randomized, double-blind, placebo controlled, phase III study of baricitinib versus placebo in patients with moderately to severely active rheumatoid arthritis and an inadequate response to methotrexate therapy: results fro |
Yang, Yue;Xu, Jianhua;Xu, Jian;Li, Xingfu;Hu, Jiankang;Li, Xiangpei;Zhang, Xiao;He, Dongyi;Bao, Chunde;Li, Zhijun;Wang, Guochun;Zerbini, Cristiano A. F.;Spindler, Alberto J.;Kannowski, Carol L.;Wu, Hanjun;Ji, Fei;Zhan, Lujing;Liu, Mengru;Li, Zhanguo |
| 2018 |
Similar Efficacy and Safety of Biosimilar Candidate IBI303 and Reference Products of Adalimumab in Patients with Ankylosing Spondylitis: Results from a Randomized, Double-Blind, Phase III Study |
Xu Huji;Li Zhijun;Jian, Wu;Qian, Xing;Shi, Guixiu;Juan, Li;Xu, Liu;Wu, Lijun;Li Xiaomei;Tan Wenfeng;He, Dongyi;Bi Liqi;Li Hongbin;Xiao Zhengyu;Shuai Zongwen;Li Xiaoxia;Wang Yongfu;Li, Luo;Yi, Zheng;Xiao Weiguo;Hui, Zhou;Lu Yushan;Zheng Shirui;Xiong, Wang |
| 2017 |
The usage of biological DMARDs and clinical remission of rheumatoid arthritis in China: a real-world large scale study |
An, Yuan;Liu, Tian;He, Dongyi;Wu, Lijun;Li, Juan;Liu, Yi;Bi, Liqi;Zhou, Bin;Lin, Changsong;He, Lan;Liu, Xiangyuan;Li, Xiaofeng;Yang, Niansheng;Zhang, Zhuoli;Song, Hui;Wei, Wei;Liu, Jing;Bi, Yu;Li, Zhanguo |
